Bladder Cancer Diagnostics Market Size To Reach USD 3,916.5 Million In 2032

2025-09-02 03:05:15

(MENAFN- Market Press Release) September 2, 2025 12:36 am - The Bladder Cancer Diagnostics market, valued at USD 1,999.6 million in 2024, is expected to register robust revenue CAGR of 8.7%. Request free copy of this report:

September 02, 2025- The expanding application of near-infrared spectroscopy (NIRS) in pharmaceuticals and healthcare is a key factor driving revenue growth in the market. NIRS is a noninvasive technique used to measure tissue oxygen saturation in organs such as the brain, kidneys, and gut. By analyzing changes in the attenuation of near-infrared light passing through the brain, it provides measurements of cerebral regional oxygen saturation (CrSO?). In neonatal intensive care units (NICUs), NIRS has become increasingly valuable for monitoring extremely preterm infants and neonates with conditions such as encephalopathy, congenital heart disease (CHD), anemia, respiratory distress, and brain injury.

In September 2024, SpectraWAVE, Inc.-a medical imaging company dedicated to enhancing treatment and outcomes for patients with coronary artery disease (CAD)-secured a USD 50 million Series B funding round. The investment was led by Johnson & Johnson Innovation – JJDC, Inc., with participation from S3 Ventures, Lumira Ventures, SV Health Investors, Deerfield Management, NovaVenture, and Heartwork Capital, underscoring investor confidence in NIRS-related innovations.

Beyond healthcare, rapid, and accurate analysis is becoming increasingly critical for quality assurance, authenticity testing, and food safety in the evolving food industry landscape. Near-infrared spectroscopy has gained strong traction as a non-destructive, fast, and environmentally friendly analytical tool due to its versatility. However, its widespread integration into regulatory frameworks remains limited, with only 25 internationally recognized analytical method documents currently endorsing its application.

Want to Know What's Fueling the Bladder Cancer Diagnostics Market Growth? Get Exclusive Report Insights Here:

Segments market overview and growth Insights
Based on test type, the bladder cancer diagnostics market is segmented into urine culture test, urine biomarker tests, imaging tests, invasive diagnostic procedures, and others. The invasive diagnostic procedures segment accounted for the largest market share in 2024. Cystoscopy remains the standard approach for diagnosing bladder cancer, as it is considered low-risk and enables both biopsy sampling and the removal of papillary tumors in a single procedure. Typically performed as an outpatient intervention under general anesthesia, cystoscopy with bladder biopsies provides effective diagnostic and therapeutic benefits. Flexible cystoscopy offers accuracy comparable to rigid cystoscopy but is significantly better tolerated, particularly among male patients.

Regional market overview and growth insights
Europe held the largest market share in the Bladder Cancer Diagnostics market in 2024. The market is being driven by rising incidence of bladder cancer and technological advancements in diagnostic methods. In the United States, bladder cancer ranks as the fourth most common cancer among men, the eighth among women, and the fifth overall, with men being affected about four times more often than women. According to the National Cancer Institute, there were 82,290 newly diagnosed cases and 16,710 deaths from bladder cancer in 2023. The disease represents 4.2% of all new cancer cases and 2.7% of all cancer-related deaths in the country, with a reported 5-year relative survival rate of 77.9%.

Competitive Landscape and Key Competitors
The Bladder Cancer Diagnostics market is characterized by a fragmented structure, with many competitors holding a significant share of the market. list of major players included in the Bladder Cancer Diagnostics market report are:

oAbbott
oCepheid
oA. Menarini Diagnostics s.r.l
oVeracyte, Inc.
oExact Sciences
oPacific Edge
oQIAGEN
oNanoentek
oNonagen Bioscience Corporation
oSysmex Corporation
oVitaDX
oPangea Laboratory
oAIRA Matrix
oKARL STORZ
oNatera, Inc.

Buy Your Exclusive Copy Now:

Major strategic developments by leading competitors
Roche: In September 2024, Roche broadened its digital pathology open platform by integrating over 20 advanced artificial intelligence (AI) algorithms developed through collaborations with eight new partners. These partnerships are designed to support pathologists and researchers in cancer detection and research by leveraging state-of-the-art AI innovations.

Scinvivo: In February 2024, Scinvivo, a medtech company based in Eindhoven focused on advancing bladder cancer diagnostics, secured Euro 4.7 million in funding from Santec OIS Corporation and The NLC Health Impact Fund. The investment will support the development of its catheter, OCT system, and accompanying software, with the goal of enabling clinical use and increasing adoption among urologists.

Unlock the Key to Transforming Your Business Strategy with Our Bladder Cancer Diagnostics Market Insights –
.Download the report summary:
.Request customization:

Navistrat Analytics has segmented the Bladder Cancer Diagnostics market based on test type, technology, cancer type, end-use, and region:
.Test Type Outlook (Revenue, USD Million; 2022-2032)
oUrine Culture Test
oUrine Biomarker Tests
oImaging Tests
oInvasive Diagnostic Procedures
oOthers

.Technology Outlook (Revenue, USD Million; 2022-2032)
oImmunoassay
oFlow Cytometry
oFluorescence In Situ Hybridization (FISH)
oPCR and NGS
oChromatography & Mass Spectrometry

.Cancer Type Outlook (Revenue, USD Million; 2022-2032)
oTransitional cell bladder cancer
oInvasive bladder cancer
oSuperficial bladder cancer
oSquamous cell bladder cancer
oOthers

.End-Use Outlook (Revenue, USD Million; 2022-2032)
oHospitals
oDiagnostic Centers
oAcademic Institutions
oAmbulatory Surgical Center

.Regional Outlook (Revenue, USD Million; 2022-2032)
oNorth Benelux
g Countries
h of Europe
oAsia Pacific
a Japan
d Oceania
f Countries
g of APAC
oLatin Brazil
b of LATAM
oMiddle East & Africa
a Countries
b Turkey
e of MEA

Get a preview of the complete research study:

About Us:
At Navistrat Analytics, we provide high-quality, comprehensive syndicated and customized market research reports that deliver actionable insights and empower businesses through data-driven strategies. Choose Navistrat Analytics as your strategic growth partner for reliable market intelligence, and let us help you navigate the complexities of the market with clarity, precision, and confidence.

MENAFN02092025003520003262ID1110004001

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.